Atara Biotherapeutics (ATRA) Competitors

Atara Biotherapeutics (NASDAQ:ATRA) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.

Does the MarketBeat Community favor ATRA or FDMT?

Atara Biotherapeutics received 378 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 67.33% of users gave Atara Biotherapeutics an outperform vote while only 65.56% of users gave 4D Molecular Therapeutics an outperform vote.

Company	Underperform	Outperform
Atara Biotherapeutics	Outperform Votes 437 67.33%	Underperform Votes 212 32.67%
4D Molecular Therapeutics	Outperform Votes 59 65.56%	Underperform Votes 31 34.44%

Does the media refer more to ATRA or FDMT?

In the previous week, Atara Biotherapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for Atara Biotherapeutics and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.78 beat Atara Biotherapeutics' score of 0.10 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
4D Molecular Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in ATRA or FDMT?

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 3.7% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has stronger earnings & valuation, ATRA or FDMT?

4D Molecular Therapeutics has lower revenue, but higher earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$199.73M	0.21	-$276.13M	-$3.72	-1.92
4D Molecular Therapeutics	$23K	7,029.32	-$100.84M	-$3.18	-1.10

Which has more risk & volatility, ATRA or FDMT?

Atara Biotherapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500.

Do analysts rate ATRA or FDMT?

Atara Biotherapeutics presently has a consensus price target of $17.75, suggesting a potential upside of 148.60%. 4D Molecular Therapeutics has a consensus price target of $29.56, suggesting a potential upside of 746.86%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
4D Molecular Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Is ATRA or FDMT more profitable?

4D Molecular Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Atara Biotherapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-132.58%	N/A	-90.16%
4D Molecular Therapeutics	N/A	-28.00%	-26.16%

Summary

4D Molecular Therapeutics beats Atara Biotherapeutics on 12 of the 19 factors compared between the two stocks.